NasdaqGS:RAREBiotechs
Why Ultragenyx (RARE) Is Up 7.8% After Reporting Narrowed Losses and Higher Q2 Revenue
Ultragenyx Pharmaceutical Inc. recently reported its second quarter 2025 earnings, revealing revenue of US$166.5 million and a net loss of US$114.95 million, both improved compared to the prior year period.
This marks the company's continued progress in narrowing losses and growing top-line revenue while advancing treatments for rare genetic diseases.
We'll explore how Ultragenyx's improved revenue and reduced net loss in Q2 2025 influence its trajectory in rare disease therapies.
Trump's...